Podcast Synopsis of Updates to the European Renal Best Practice and UK Kidney Association Guidelines for Treatment of Anaemia in Chronic Kidney Disease

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) were developed as an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia of chronic kidney disease (CKD). In 2024, the European Renal Best Practice Board (ERBP) of the European Renal Association published a clinical practice document for the use of HIF-PHIs; in 2025, the UK Kidney Association (UKKA) updated its treatment guidelines for anaemia of CKD, including HIF-PHIs as a recommended additional therapy. This podcast provides an overview of HIF-PHIs compared to ESAs, followed by a summary of general recommendations for the treatment of anaemia of CKD, with reference to both ERBP and UKKA guidelines. Considerations for prescribing ESAs and HIF-PHIs to specific patient groups, including those with inflammation, a history of cancer or cardiovascular events, kidney transplant recipients, and hospitalised patients, are then discussed.